Novartis: new data for psoriatic arthritis

(CercleFinance.com) - Novartis has announced new data from the FUTURE 5 trial showing no radiographic progression in nearly 90% of patients with Cosentyx psoriatic arthritis (secukinumab) 300 mg over 2 years.


Data at 2 years show that more than 50% of adults with active PsA reached ACR50 and nearly 50% achieved a PASI 100 response with Cosentyx 300 mg.

"Results strengthen unique position of Cosentyx as a rapid, comprehensive treatment of spondyloarthritis and psoriatic disease, with over 200,000 patients treated worldwide," the group said.

"PsA is a complex disease with multiple manifestations driving patient symptoms[3],[4]. It is estimated to affect up to 50 million people wordwide[5-8] and is part of a family of long-term inflammatory diseases (spondyloarthritis) that target the joints," it added.


Copyright (c) 2019 CercleFinance.com. All rights reserved.